Pharmacotherapy Original research| Volume 34, ISSUE 9, P1920-1928, September 2012

Effects of a Supratherapeutic Dose of Investigational Orally Inhaled Dihydroergotamine (MAP0004) on QT Interval: A Randomized, Double-Blind, Active- and Placebo-Controlled Crossover Study in Healthy Volunteers



      MAP0004 is an orally inhaled investigational drug containing dihydroergotamine (DHE). Although DHE has been used for 60 years with no reported cardiac arrhythmias, a thorough QT study had not previously been performed with DHE.


      The objective of this study was to assess the effects of MAP0004 on the QT interval as required for regulatory approval of a new product.


      This randomized, double-blind, placebo-controlled, 3-period crossover study enrolled healthy volunteers. Subjects were assigned to receive, in randomized sequence, MAP0004 at a supratherapeutic dose (3-fold the clinically effective dose) (3.0 mg), moxifloxacin 400 mg, or inactive vehicle, each administered with 1 placebo capsule. Triplicate ECGs were performed continuously at baseline (day 0), before dosing, and over 24 hours after dosing in each treatment period. The effect on the QT interval was assessed using the Fridericia (QTcF) and individualized (QTcI) correction formulas.


      Fifty-four healthy adults (20 men, 34 women; mean age, 28 years) completed the trial and had measurable plasma levels of DHE after MAP0004 administration. The largest observed mean difference in QTcI between MAP0004 and placebo was 0.08 msec, and the largest 1-sided 95% upper confidence bound was 2.24 msec, both at 30 minutes after dosing. In contrast, moxifloxacin increased the mean QTcI between 9.57 and 11.28 msec relative to placebo, with a 1-sided lower 95% CL between 7.23 and 8.96 msec, confirming that the assay sensitivity was sufficient to detect MAP0004-related effects. Nausea (27.8%) was common following MAP0004 administration but apparently did not influence the QTc interval.


      A supratherapeutic dose of MAP0004 was not associated with prolonged QTc intervals. At the proposed clinical dose (1.0 mg), MAP0004 is unlikely to affect the QT interval. MAP0004 and its primary metabolite showed no evidence for prolongation of the QTc interval in healthy subjects according to the criteria required from regulatory agencies. identifier: NCT01191723.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Silberstein S.D.
        • McCrory D.C.
        Ergotamine and dihydroergotamine: history, pharmacology, and efficacy.
        Headache. 2003; 43: 144-166
        • Velentgas P.
        • Cole J.A.
        • Mo J.
        • et al.
        Severe vascular events in migraine patients.
        Headache. 2004; 44: 642-651
        • Wammes-van der Heijden E.A.
        • Rahimtoola H.
        • Leufkens H.G.
        • et al.
        Risk of ischemic complications related to the intensity of triptan and ergotamine use.
        Neurology. 2006; 67: 1128-1134
        • US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research
        Guidance for Industry.
        • Baron E.P.
        • Tepper S.J.
        Orally inhaled dihydroergotamine.
        Future Neurol. 2011; 6: 327-333
        • Aurora S.K.
        • Rozen T.D.
        • Kori S.
        • Shrewsbury S.B.
        A randomized, double blind, placebo controlled study of MAP0004 in adult patients with migraine.
        Headache. 2009; 49: 826-837
        • Aurora S.K.
        • Silberstein S.D.
        • Kori S.H.
        • et al.
        MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine.
        Headache. 2011; 51: 507-517
        • Shrewsbury S.B.
        • Stonerook M.
        • Okikawa J.K.
        Intrapulmonary and intravenous administrations of dihydroergotamine mesylate (DHE) have similar cardiovascular effects in the conscious dog.
        Br J Pharmacol. 2008; 154: 1254-1265
        • Berenberg E.
        • Clemons D.
        • Kellerman D.
        • et al.
        A randomized, double-blind, placebo-controlled, three-period crossover study comparing the acute effects of LEVADEX (MAP0004, orally inhaled DHE) and intravenous DHE on pulmonary arterial systolic pressure.
        Headache. 2011; 51: 23
        • Stovner L.j.
        • Hagen K.
        • Jensen R.
        • et al.
        The global burden of headache: a documentation of headache prevalence and disability worldwide.
        Cephalalgia. 2007; 27: 193-210
        • Shrewsbury S.B.
        • Cook R.O.
        • Taylor G.
        • et al.
        Safety and pharmacokinetics of dihydroergotamine mesylate administered via a novel (Tempo) inhaler.
        Headache. 2008; 48: 355-367
        • Shrewsbury S.B.
        • Kori S.
        • Miller S.D.
        • et al.
        Randomized, double blind, placebo controlled study of the safety, tolerability and pharmacokinetics of MAP0004 (orally-inhaled DHE) in adult asthmatics.
        Curr Med Res Opin. 2008; 24: 1977-1985
        • Forst A.
        • Febbraro S.
        • Kellerman D.
        • et al.
        An open-label, two-period crossover study comparing the pharmacokinetics and tolerability of LEVADEX (MAP0004, orally inhaled DHE) and intravenous DHE (DHE45®) in smoking and non-smoking adult volunteers.
        Headache. 2011; 51 (Abstract P31): 17
        • Armer T.A.
        • Lynch M.
        • Moutvic R.
        • Singer A.
        Toxicological assessment of dihydroergotamine after chronic inhalation in dogs.
        Toxicol Pathol. 2011; 39: 544-552